האיחוד האירופי - פורטוגלית - EMA (European Medicines Agency)

sanofi winthrop industrie - aflibercept - neoplasias colorretais - agentes antineoplásicos - tratamento do câncer colorretal metastático (mcrc).

האיחוד האירופי - פורטוגלית - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agentes para dermatite, excluindo corticosteróides - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

ברזיל - פורטוגלית - ANVISA (Agência Nacional de Vigilância Sanitária)

sanofi-aventis farmacÊutica ltda - insulina glargina - antidiabeticos

ברזיל - פורטוגלית - ANVISA (Agência Nacional de Vigilância Sanitária)

sanofi-aventis farmacÊutica ltda - antineoplasico

ברזיל - פורטוגלית - ANVISA (Agência Nacional de Vigilância Sanitária)

sanofi medley farmacÊutica ltda. - alirocumabe - antilipemicos

ברזיל - פורטוגלית - ANVISA (Agência Nacional de Vigilância Sanitária)

sanofi medley farmacÊutica ltda. - insulina glulisina - antidiabeticos

ברזיל - פורטוגלית - ANVISA (Agência Nacional de Vigilância Sanitária)

sanofi medley farmacÊutica ltda. - oxaliplatina - citostaticos alquilantes

האיחוד האירופי - פורטוגלית - EMA (European Medicines Agency)

sanofi winthrop industrie - isatuximab - mieloma múltiplo - agentes antineoplásicos - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

האיחוד האירופי - פורטוגלית - EMA (European Medicines Agency)

sanofi winthrop industrie - insulina aspart - diabetes mellitus - drogas usadas em diabetes - truvelog mix 30 is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 10 years and above.

האיחוד האירופי - פורטוגלית - EMA (European Medicines Agency)

sanofi b.v. - sutimlimab - hemolysis; anemia, hemolytic, autoimmune - imunossupressores - enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (cad).